Publications

Authors:

Adami, G.; Idolazzi, L.; Benini, C.; Fracassi, E.; Carletto, A.; Viapiana, O.; Gatti, D.; Rossini, M.; Fassio, A.

Title:

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

Year:

2023

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Reumatismo

ISSN of journal:

0048-7449

N° Volume:

75

Number or Folder:

1

Page numbers:

28-34

Keyword:

Secukinumab; Psoriatic arthritis; Retention rate; Tumor necrosis factor inhibitors; Axial psoriatic arthritis; Spondylarthritis

Short description of contents:

: Psoriatic arthritis (PsA) is an inflammatory disease characterized by peripheral and axial involvement. Biological disease-modifying antirheumatic drugs (bDMARDs) are the mainstream treatment for PsA and bDMARDs retention rate is a proxy for the drug's overall effectiveness. However, it is unclear whether IL-17 inhibitors can have a higher retention rate than tumor necrosis factor (TNF) inhibitors, in particular in axial or peripheral PsA. A real-life observational study was conducted on bDMARD naïve PsA patients initiating TNF inhibitors or secukinumab. Time-to-switch analysis was carried out with Kaplan-Meyer curves (log-rank test) truncated at 3 years (1095 days). Sub-analyses of Kaplan-Meyer curves between patients presenting with prevalent peripheral PsA or prevalent axial PsA were also conducted. Cox regression models were employed to describe predictors of treatment switch/swap. Data on 269 patients with PsA naïve to bDMARD starting either TNF inhibitors (n=220) or secukinumab (n=48) were retrieved. The overall treatment retention at 1 and 2 years was similar for secukinumab and TNF inhibitors (log-rank test p NS). We found a trend towards significance in the Kaplan-Meyer at 3 years in favor of secukinumab (log-rank test p 0.081). Predominant axial disease was significantly associated with a higher chance of drug survival in secukinumab users (adjusted hazard ratio 0.15, 95% confidence interval = 0.04-0.54) but not in TNF inhibitor users. In this real-life, single-center, study on bDMARD naïve PsA patients, axial involvement was associated with longer survival of secukinumab but not of TNF inhibitors. Drug retention of secukinumab and TNF inhibitors were similar in predominantly peripheral PsA.

Product ID:

133766

Handle IRIS:

11562/1093971

Last Modified:

October 30, 2024

Bibliographic citation:

Adami, G.; Idolazzi, L.; Benini, C.; Fracassi, E.; Carletto, A.; Viapiana, O.; Gatti, D.; Rossini, M.; Fassio, A., Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement «Reumatismo» , vol. 75 , n. 1 , 2023 , pp. 28-34

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo